Madrigal Pharmaceuticals (MDGL) FCF Margin (2010 - 2026)
Madrigal Pharmaceuticals' (MDGL) quarterly FCF Margin came in at 55.02% in Q1 2026, up 975.0% year-on-year from 5.12% in Q1 2025, and down 32.62% on a QoQ basis from 41.48% in Q4 2025.
Madrigal Pharmaceuticals (MDGL) FCF Margin (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 6 years of FCF Margin data on file, last reported at 55.02% in Q1 2026.
- On a quarterly basis, FCF Margin rose 975.0% year-over-year to 55.02% in Q1 2026; TTM through Mar 2026 was 24.05%, a 10085.0% increase from a year earlier, with the FY2025 full-year figure at 19.83%, up 23389.0% from the prior year.
- FCF Margin for Q1 2026 stood at 55.02%, down from 41.48% in the prior quarter.
- Over the last five years, FCF Margin for MDGL reached as high as 27.54% in Q3 2025 and fell as low as 922.78% in Q2 2024.
- Historically, FCF Margin has averaged 161.01% across 3 years, with a median of 59.89% in 2025.
- Across the five-year window, FCF Margin soared 90067 bps in 2025 and jumped 975 bps in 2026, its largest moves.
- Year by year, FCF Margin stood at 102.54% in 2024, then jumped by 60 bps to 41.48% in 2025, then plunged by 33 bps to 55.02% in 2026.
- Per Business Quant data, the three most recent FCF Margin figures were 55.02% in Q1 2026, 41.48% in Q4 2025, and 27.54% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Madrigal Pharmaceuticals | 15.79 Bn | 15.56 Bn | - | -55.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.02% |
| Dec 31, 2025 | -41.48% |
| Sep 30, 2025 | 27.54% |
| Jun 30, 2025 | -22.11% |
| Mar 31, 2025 | -64.77% |
| Dec 31, 2024 | -102.54% |
| Sep 30, 2024 | -106.95% |
| Jun 30, 2024 | -922.78% |
| Sep 30, 2012 | -28,593.88% |
| Jun 30, 2012 | -19,197.96% |
| Mar 31, 2012 | -10,476.87% |
| Dec 31, 2011 | -9,100.83% |
| Sep 30, 2011 | -717.55% |
| Jun 30, 2011 | -5,776.78% |
| Mar 31, 2011 | -1,124.15% |
| Dec 31, 2010 | -200.92% |
| Sep 30, 2010 | -258.38% |